Do you ever get lost in your head while trying to follow recursive problems?In the autumn of 2025, a junior colleague asked ...
Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...
In an amended S-1/A filing submitted to the SEC on November 2, 2026, Anthropic warned of the possibility that it is ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has counted Nvidia as an investor since 2023 when Jensen Huang's company invested ...
Operating cash use fell to $77.4M from $117.4M. Based on current operating plans and no additional financing, cash runway is expected into 2029.
Together AI builds an agentic compiler to try and bring recursive self improvement capabilities to open source models.
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +8.33% and +69.88%, respectively, for the ...
Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.
Recursion announced new positive Phase 2 data from the ongoing TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor for familial adenomatous ...
Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...
4d
Portal Innovations and Altitude Lab Partner to Strengthen Utah’s Life Sciences Startup Ecosystem
Portal Innovations, a venture development platform supporting early-stage life sciences companies, today announced a ...
A Google DeepMind and Stanford study finds simple shapes like a red heart can push AI models such as GPT-5.4 and Claude ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results